Summarized by Masters of Longevity from Longevity Technology.
News item about progress in a clinical trial testing a new oral obesity therapy combined with an approved GLP-1 drug; a concise enrollment update and study focus to preview.
Key Takeaways
- The FORGE-LM Phase 2 study has reached about 50% of its targeted enrollment.
- SIR4156 is an oral allosteric NAMPT activator being tested alongside semaglutide in adults with obesity.
